Press Releases

June 22 - Nurosene Enters Into Agreement with Taylored Biotherapeutics to Evaluate Clinical Trial Results

June 8 - Nurosene Health Inc. Announces Closing of Private Placement

June 8 - Nurosene's Chief Scientific Officer to Present at World Orphan Drug Congress USA 2022

May 27 - Nurosene Enters Into Agreement with a Speciality Biopharma Company to Generate Insights from Clinical Trial Results

May 19 - Nurosene's Chief Scientific Officer Publishes Paper on AI and Placebo Response

May 18 - Nurosene Completes Population Stratification Project For Major Pharmaceutical Company

May 6 - Nurosene Announces Strategic Agreement with Brain Analysis Platform, Cove Neurosciences Inc.

April 19 - Nurosene Initiates Research on Nuro App in Collaboration with Dalhousie University

April 13 - Nurosene Announces Research Partnership in Oncology with The Ontario Institute for Cancer Research

April 7 - Nurosene Appoints Seasoned Finance Executive Gino DeMichele to Board of Directors

March 8 - Nurosene's CSO And Director Of Bioinformatics Receives 'Highly Cited Paper' Award For AI-Based Alzheimer's Research Findings

View All +

Financial Reporting

Q3 2021 - Interim Financial Results

Q3 2021 - MD&A

Corporate Governance

Notice of Meeting & MIC for AGM - April 1, 2022

Proxy - AGM 2022

Code Business Conduct and Ethics

Audit Committee Charter

Nurosene

[Head Office]

1655 Dupont St. #Suite 101

Toronto, ON M6P 3S9

investors@nurosene.com

Fasken Martineau DuMoulin LLP

[Legal]

2400 - 333 Bay St.

Toronto, ON M5H 2T6

416.366.8381

MNP LLP

[Auditors]

111 Richmond St. W Suite 300

Toronto, ON M5H 2G4

416.596.1711

Odyssey Trust

[Transfer Agent]

United Kingdom Building 323

409 Granville Street

Vancouver, BC V6C 1T2

1.833.392.7716